Table 4b.
Multivariate Cox proportional regression analysis among all patients according to PPI use before and after PSM
| Clinical endpoint | Before PSM | After PSM | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Primary endpoint | ||||
| MACCE | 1.049 (0.854–1.289) | 0.651 | 0.970 (0.808–1.165) | 0.745 |
| Secondary endpoint | ||||
| All cause death | 0.775 (0.410–1.465) | 0.433 | 0.935 (0.534–1.634) | 0.812 |
| MI | 0.838 (0.508–1.383) | 0.490 | 0.904 (0.597–1.368) | 0.634 |
| Unplanned TVR | 1.042 (0.822–1.322) | 0.733 | 0.992 (0.798–1.233) | 0.942 |
| Stent thrombosis | 0.964 (0.451–2.064) | 0.925 | 0.736 (0.380–1.425) | 0.363 |
| Stroke | 2.171 (0.896–5.258) | 0.086 | 0.730 (0.409–1.302) | 0.286 |
| Safety endpoint | ||||
| Bleeding | 1.094 (0.821–1.458) | 0.539 | 0.841 (0.651–1.086) | 0.184 |
| BARC 3 or 5 | 0.572 (0.218–1.502) | 0.257 | 0.341 (0.103–1.132) | 0.079 |
| GI bleeding | 0.800 (0.455–1.409) | 0.440 | 0.586 (0.341–1.009) | 0.054 |
PPI: Proton-pump inhibitors; PSM: Propensity score matching; HRs: Hazard ratios; CIs: Confidence intervals; MACCE: Major adverse cardiovascular and cerebrovascular events; MI: Myocardial infarction; TVR: Target vessel revascularization; BARC: Bleeding Academic Research Consortium; GI: Gastrointestinal.